Keep an eye on Altria Group (MO).
For one, the stock is brutally oversold on RSI, MACD, and Williams’ %R. It’s also oversold at double bottom support dating back to December 2021. All after the US FDA banned all of Juul Labs’ vape products from the U.S.
In fact, the agency noted:
“The U.S. Food and Drug Administration issued marketing denial orders (MDOs) to JUUL Labs Inc. for all of their products currently marketed in the United States. As a result, the company must stop selling and distributing these products. In addition, those currently on the U.S. market must be removed, or risk enforcement action. The products include the JUUL device and four types of JUUL pods: Virginia tobacco flavored pods at nicotine concentrations of 5.0% and 3.0% and menthol flavored pods at nicotine concentrations of 5.0% and 3.0%. Retailers should contact JUUL with any questions about products in their inventory.”
Two, the stock’s 8.52% dividend looks safe.
According to Stifel analyst Chris Growe, who has a buy rating on the stock, says the dividend is vital to the investor base. “It is absolutely necessary for their stock, and I think that most investors expect it,” he said, as quoted by Barron’s. “They are growing their profit, and they are growing their free cash flow each and every year.”
Weakness may be opportunity in Altria (MO).